Novo Nordisk A/S
Copenhagen Stock Exchange NOVO-B.CO
Novo Nordisk A/S Return on Assets (ROA) for the year ending December 31, 2023: 26.61%
-
Novo Nordisk A/S Return on Assets (ROA) for the year ending December 31, 2022 was 23.01%, a -6.26% change year over year.
-
Novo Nordisk A/S Return on Assets (ROA) for the year ending December 31, 2021 was 24.55%, a -15.56% change year over year.
-
Novo Nordisk A/S Return on Assets (ROA) for the year ending December 31, 2020 was 29.08%, a -6.23% change year over year.
-
Novo Nordisk A/S Return on Assets (ROA) for the year ending December 31, 2019 was 31.01%, a -11.08% change year over year.
| Date | Return on Assets (ROA) | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio |
|---|
| CEO | Mr. Lars Fruergaard Jorgensen |
| IPO Date | Jan. 6, 2001 |
| Location | Denmark |
| Headquarters | Novo Alle 1 |
| Employees | 71,880 |
| Sector | Health Care |
| Industries | |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Past 5 years
USD 26.62
USD 40.61
USD 29.25
USD 204.21
USD 13.03
StockViz Staff
January 15, 2025
Any question? Send us an email